Pharminent

Canvas Paints A Mixed Picture For J&J’s Invokana

https://seekingalpha.com/article/4081122-canvas-paints-mixed-picture-j-and-js-invokana

Filed under: Diabetes, SGLT-2

AstraZeneca study shows cardiovascular benefit to SGLT-2 drugs

The British pharma hopes the results, assessed from real-world data, will help boost use of the newer class of diabetes drugs.  http://www.biopharmadive.com/news/astrazeneca-cvd-real-sglt2-diabetes-farxiga/438425/

Filed under: Diabetes, SGLT-2

Eli Lilly, Boehringer secure CV label for Jardiance

The FDA gave the companies an early Christmas present, approving an expanded indication for the diabetes drug which Lilly hopes will be a catalyst for sales.  http://www.biopharmadive.com/news/eli-lilly-boehringer-secure-cv-label-for-jardiance/431587/

Filed under: Diabetes, SGLT-2

NICE backs use of Forxiga in triple therapy for diabetes

The National Institute for Health and Care Excellence has now published final draft guidelines endorsing NHS use of AstraZeneca’s Forxiga for treating type II diabetes as part of a ‘triple therapy’. http://www.pharmatimes.com/news/nice_backs_use_of_forxiga_in_triple_therapy_for_diabetes_1155532

Filed under: Diabetes, SGLT-2

AZ trials diabetes drug Forxiga in kidney disease, heart failure

AstraZeneca has launched two new trials with its SGLT-2 inhibitor Forxiga (dapagliflozin) exploring its potential beyond the drug’s approved diabetes indication. http://www.pharmatimes.com/news/az_trials_diabetes_drug_forxiga_in_kidney_disease,_heart_failure_1129886

Filed under: Diabetes, SGLT-2

U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults

U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults https://investor.lilly.com/releasedetail.cfm?ReleaseID=980079

Filed under: Diabetes, SGLT-2

Jardiance Mortality Claim Narrowly Endorsed By FDA Advisory Committee

The 12-11 vote supporting new indication for reduced incidence of cardiovascular death provides cover for FDA if it decides more data are needed before granting first CV benefit claim to a diabetes drug. https://www.pharmamedtechbi.com/Publications/The-Pink-Sheet-Daily/2016/6/28/Jardiance-Mortality-Claim-Narrowly-Endorsed-By-FDA-Advisory-Committee

Filed under: Diabetes, SGLT-2

FDA expands indication for Janssen Pharmaceuticals’ Invokamet diabetes drug

The US Food and Drug Administration (FDA) has approved an expanded indication for Janssen Pharmaceuticals’ Invokamet diabetes medication. http://regulatoryaffairs.pharmaceutical-business-review.com/news/fda-expands-indication-for-janssen-pharmaceuticals-invokamet-diabetes-drug-250516-4902924

Filed under: Diabetes, SGLT-2

Canagliflozin/Metformin Combo Approved as First Line for Diabetes

The fixed-dose combination product of canagliflozin and metformin, known as Invokamet, has been approved for first-line treatment of type 2 diabetes in the US. News Alerts http://www.medscape.com/viewarticle/863737

Filed under: Diabetes, SGLT-2

Eli Lilly And Boehringer Reveals Study On Jardiance For Treatment Heart Failure

http://finance.yahoo.com/news/eli-lilly-boehringer-reveals-study-110421858.html

Filed under: Diabetes, SGLT-2

News and press releases: EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes

Healthcare professionals should be aware of possible atypical cases http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/02/news_detail_002477.jsp&mid=WC0b01ac058004d5c1

Filed under: Diabetes, SGLT-2

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin) https://investor.lilly.com/releasedetail.cfm?ReleaseID=951493

Filed under: Diabetes, SGLT-2

VIDEO: Positive CV outcomes with SGLT2 inhibitors mark ‘an exciting time’

http://www.healio.com/cardiology/diabetes/news/online/%7B35231e5f-4ba9-468c-8ab8-c8ef5dce79de%7D/video-positive-cv-outcomes-with-sglt2-inhibitors-mark-an-exciting-time

Filed under: Diabetes, SGLT-2

Eli Lilly’s diabetes pill takes market share from J&J, Astra

http://www.reuters.com/article/us-eli-lilly-diabetes-idUSKBN0UJ2AQ20160105

Filed under: Diabetes, SGLT-2

Lilly lowers financial expectations, but sees Jardiance boost

Lilly lowers financial expectations, but sees Jardiance boost http://pharmatimes.com/Article/16-01-06/Lilly_lowers_financial_expectations_but_sees_Jardiance_boost.aspx

Filed under: Diabetes, SGLT-2

Game-Changers in Cardiology: Jardiance Heart Benefit

(MedPage Today) — A diabetes drug that benefits the heart http://www.medpagetoday.com/Cardiology/Diabetes/55437

Filed under: Diabetes, SGLT-2

SGLT-2 Inhibitor Reduces Risk of Cardiovascular Death: Should Current Guidelines be Impacted?

http://www.diabetesincontrol.com/sglt-2-inhibitor-reduces-risk-of-cardiovascular-death/

Filed under: Diabetes, SGLT-2

Reducing type 2 diabetes mortality: empagliflozin study

http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/reducing-type-2-diabetes-mortality-empagliflozin-study

Filed under: Diabetes, SGLT-2

Janssen seeks US approval for extended release formulation of Invokamet for type 2 diabetes

Janssen Research & Development has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for extended release formulation of Invokamet XR to treat type 2 diabetes. http://www.pharmaceutical-business-review.com/news/janssen-seeks-us-approval-for-extended-release-formulation-of-invokamet-for-type-2-diabetes-231115-4734165

Filed under: Diabetes, SGLT-2

Can SGLT2 Inhibitors Offer Options for Type 1 Treatment?

http://www.ajmc.com/journals/evidence-based-diabetes-management/2015/november-2015/can-sglt2-inhibitors-offer-options-for-type-1-treatment

Filed under: Diabetes, SGLT-2

Categories